NASDAQ:VRDN Viridian Therapeutics Q3 2023 Earnings Report $21.65 +0.43 (+2.03%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$21.66 +0.01 (+0.02%) As of 10/3/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Viridian Therapeutics EPS ResultsActual EPS-$1.09Consensus EPS -$1.22Beat/MissBeat by +$0.13One Year Ago EPSN/AViridian Therapeutics Revenue ResultsActual Revenue$0.07 millionExpected Revenue$0.28 millionBeat/MissMissed by -$210.00 thousandYoY Revenue GrowthN/AViridian Therapeutics Announcement DetailsQuarterQ3 2023Date11/13/2023TimeN/AConference Call DateTuesday, November 14, 2023Conference Call Time8:00AM ETUpcoming EarningsViridian Therapeutics' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Viridian Therapeutics Earnings HeadlinesViridian Therapeutics: De-Risked Leadership In Thyroid Eye DiseaseSeptember 26, 2025 | seekingalpha.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.78 Consensus PT from BrokeragesSeptember 23, 2025 | americanbankingnews.comGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks say this is just the beginning... Because there's mounting evidence that a 40% market crash could be on the way.October 4 at 2:00 AM | Stansberry Research (Ad)Viridian Therapeutics completes enrollment in REVEAL-1, REVEAL-2 studiesSeptember 15, 2025 | msn.comViridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio UpdatesSeptember 15, 2025 | businesswire.comViridian Therapeutics files automatic mixed securities shelfSeptember 6, 2025 | msn.comSee More Viridian Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email. Email Address About Viridian TherapeuticsViridian Therapeutics (NASDAQ:VRDN) (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders. In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases. Both candidates are being evaluated in multiple clinical trials across North America and Europe, underscoring the company’s commitment to building a robust pipeline of precision biologics. Viridian’s research platform leverages advanced antibody engineering to enhance potency, selectivity and pharmacokinetic properties, supporting the development of differentiated therapies with the potential for best-in-class profiles. Founded in 2020 and headquartered in Boston, Massachusetts, Viridian was established by a team of experienced biotechnology entrepreneurs and scientists. The company completed its initial public offering in 2021 to secure funding for clinical development and manufacturing scale-up. Under the leadership of Chief Executive Officer Mara Aspinall and Chief Medical Officer Michael Rosenzweig, Viridian has formed strategic partnerships with contract development and manufacturing organizations to support its late-stage programs. Viridian’s global footprint extends through clinical sites and collaborative networks aimed at delivering novel treatments to patients worldwide.View Viridian Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
